Author Archives: admin


Stem Cell Clinic > Articles by: admin

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update – Stockhouse

By Stem Cell Treatment

NEW YORK, July 27, 2020 /PRNewswire/ -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2020, and provide a corporate update, at 8:00 a.m., Eastern Daylight Time (EDT), on Wednesday, August 5 2020.

On the call, BrainStorm CEO Chaim Lebovits will present a corporate update, including details on the timeline for the data readout of the Company's Phase 3 pivotal trial studying the safety and efficacy of NurOwn® (MSC-NTF cell) in people with ALS. In addition, Dr. Revital Aricha. Brainstorm's Vice President of Research and Development, will provide an R&D update including recently announced data from the Company's groundbreaking preclinical study evaluating NurOwn-derived exosomes for the treatment of COVID-19 ARDS.

Thereafter, senior management officers will join the call for a Q&A session. Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 5:00 p.m. EDT, Monday, August 3, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 2Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:

Toll Free: 877-407-9205 International: 201-689-8054

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Number:

Toll Free: 877-481-4010 International: 919-882-2331 Replay Passcode: 36017

Teleconference Replay Expiration:

Wednesday, August 19, 2020

About NurOwn®

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and initiated enrollment in March 2019.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at http://www.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations: Preetam Shah, MBA, PhD Chief Financial Officer BrainStorm Cell Therapeutics Inc. Phone: +1-862-397-1860 pshah@brainstorm-cell.com

Media: Paul Tyahla SmithSolve Phone: +1-973-713-3768 Paul.tyahla@smithsolve.com

View original content:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-announce-second-quarter-financial-results-and-provide-a-corporate-and-rd-update-301100141.html

SOURCE Brainstorm Cell Therapeutics Inc

More:
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update - Stockhouse

Unproven stem cell therapies, and now, strong words from the FDA – BioNews

By Stem Cell Clinics

27 July 2020

There has been general concern around the reports of untested stem celltreatments being sold before they have been proven safe and effective. A recent publication by the US' Food and Drug Administration (FDA)represents an informal forewarning to the rogue doctors operating outside of the regulatory regime that they may not get extra time to comply with the agency's strict regulation of regenerative medicine products.

This piece, which uses strong language, underscores the regulatory agency's firm commitment to evidence-based regenerative products.

In 2017, the FDA articulated the regulatory criteria for product marketing through the publication of four guidance documents. These documents build upon the agency's existing risk-based, flexible regulatory regime. They enable stakeholders to understand better how the regulatory criteria apply to their products by clarifying complex technical definitions such as 'minimal manipulation' and 'homologous use'.

This coming November will mark the end of the three years of enforcement discretion announced by the FDA when it first set up this stringent regulatory framework. This approach allows product manufacturers sufficient time to engage with the agency to comply with the requirements, eg, to determine whether they must submit a marketing authorisation application to the FDA for their approval. In the recent piece, there is no indication of a deadline extension.

The authors, Dr Stephen Hahn (FDA's new commissioner) and Dr Peter Marks (Centre for Biologics and Evaluation and Research (CBER) director), state that '... these products, whether autologous (taken from the patient) or allogeneic (donated), are not inherently safe and may be associated with serious adverse consequences'. This piece places the unproven stem cell therapy issue in the context of the COVID-19 pandemic, during which some clinics selling unproven stem cell therapies have exploited the fears of the vulnerable public.

It also indicates that 'the increasing number of adverse events being reported following the widespread use of unapproved regenerative medicine therapies at hundreds of clinics across the country make it necessary for the FDA to act to prevent harm to individuals receiving them.' This point is indeed commendable as it represents the increasingly proactive measures being taken by the FDA in taking enforcement action.

The authors request engagement from patients, their family and friends as well as clinicians 'to help to ensure that instead of remaining unintentionally or intentionally hidden, potentially harmful unapproved regenerative medicine therapies are identified and then removed from the market.' Some clinics may attempt to avoid being on the FDA's radar, however, there is reliable research that should help inform the FDA about the emergence of hundreds, if not a thousand such centres in the US.

Crucially, the article provides some useful and practical guidelines for patients to refer to when evaluating whether a cellular product is offered in compliance with the FDA regulations. For patients contemplating therapies involving a cellular product, the authors recommend the following steps as appropriate practices: first, they need to verify whether the product is FDA-approved or whether an investigational new drug (IND) application for the product is currently on file with the FDA. Next, the patient must provide written informed consent to participate in a clinical trial under that IND and compliance with institutional review board (IRB) requirements.

Moreover, the patient must not be charged for either the unapproved product or for participation in the clinical trial unless there is evidence of benefit to the patient, in which case the amount charged must not exceed the actual direct costs to create the product (cost recovery). And this must be documented by a certified public accountant.

On a critical note, patients (and family, friends and clinicians) are encouraged to report adverse medical events after receiving the product and the health care provider must clearly explain the specific steps for doing so, such as filling in patient-friendly forms to report the matter. Such reports will enable the FDA to get a complete picture of the range of dubious activities.

Finally, patients enrolled in the clinical trial should receive a summary of results after the clinical trial. Transparency, it is felt, will engender trust.

Interestingly, the authors state that medical professionals, including primary care physicians and nurses, are in the best position to assist patients in identifying whether the particular regenerative medicine treatment is appropriate for them to pursue. It is doubtful whether this represents an accurate position as there may be a wide range of knowledge and awareness of stem cell interventions even among the doctors.

The article, written amid a pandemic when the FDA is occupied with other pressing matters, reiterates the agency's obligation to its fundamental mission. Collectively, this piece and the recent escalation in warnings, as well as untitled letters sent by FDA to clinics proffering unapproved stem cell treatments, may indicate that these companies may not be granted more time to comply with the requirements. The remaining months may provide some inkling into what the enforcement situation is likely to be as the FDA's enforcement discretion period finishes in November 2020.

See the original post:
Unproven stem cell therapies, and now, strong words from the FDA - BioNews

HKUMed reveals pathogenic gene of carpal tunnel syndrome providing new directions for prevention and treatment – Mirage News

By Stem Cell Treatment

The LKS Faculty of Medicine of The University of Hong Kong (HKUMed), in collaboration with China-Japan Union Hospital of Jilin University, Mainland China, Harvard University and National Institutes of Health (NIH), U.S., have discovered that genetic mutation is one of the key risk factors of carpal tunnel syndrome (CTS). The study revealed a previously unrecognized mechanism in CTS pathogenesis and provided new insight into the development of new preventive and therapeutic strategies. The findings are now published in the leading multidisciplinary science journal Nature Communications [link to the publication].

Background

CTS, sometimes also known as mouse hand, is a fairly common condition in people, who have repeated and forceful movements of the hand and the wrist in their work and daily life, such as I.T. professionals, construction workers, cleaners and housewives. CTS is characterized by pain, numbness, tingling and weakness in the hand and the wrist due to excessive pressure on the median nerve within the carpal tunnel, which is often caused by swelling and thickening of soft connective tissues surrounding the median nerve.

CTS is a progressive disorder that can worsen without appropriate treatment, leading to nerve damage, permanent muscle atrophy, or loss of hand function. It is estimated to affect 1-5% of the general population[1] and is a leading cause of work disability. It is more common in people older than 40, and women are more likely to develop the condition than men; and more than one-half of cases will experience bilateral symptoms. According to the 0.1-0.3% incidence of CTS in U.S., the number of new cases in Hong Kong is estimated to be at least 7,000 per year[2].

In the past, most people believed that environmental factors, such as repetitive use of hands and wrists, were the main causes of CTS. However, familial occurrence of CTS in 1739% of cases[3] [4], a number of CTS families reported over the world and a large twin study that found an approximate 46% genetic contribution[5], suggest that genetic factors significantly influence CTS susceptibility. Nevertheless, so far, no causal genes were identified.

Research findings

It is challenging to study the pathogenesis of complex human diseases due to their multifactorial and polygenic nature, but Mendelian forms of common diseases have proven invaluable in identifying disease genes and elucidating pathogenic mechanisms. In this study, the research team analyzed two large pedigrees of CTS (nearly 100 cases) by using clinical, genetic, histological and biochemical methods. They discovered that mutations in a gene called COMP caused CTS in these two families.

COMP is highly expressed in the soft connective tissues surrounding the median nerve. The mutant COMP induced cellular stress response, leading to an accumulation of fibrotic and adipogenic cells. Eventually, fibrotic connective tissues in the human carpal tunnel become thickened and swollen, thus compressing the median nerve in causing CTS. Scientists further generated a CTS animal model, which recapitulated the progressive phenotype of human patients, and found that injury could significantly accelerate CTS onset.

Our findings provide solid evidence that genetic mutations can cause CTS, and COMP is the first identified causative gene. We also revealed cellular stress response as a novel mechanism underlying the pathogenesis of CTS, which lays the foundation for the future development of new treatments by inhibiting such response, said Dr Gao Bo, Assistant Professor of the School of Biomedical Sciences, HKUMed, who led the research.

The onset time and symptoms of familial patients are usually earlier and stronger than sporadic patients because the major risk factor is intrinsic (e.g. genetic) rather than extrinsic (e.g. life style, occupation). But sporadic CTS more likely result from combined effects of genetic susceptibility and environmental factors. When consulting a doctor, the patient should inform whether there are other affected members in his/her family, which will assist in diagnosis. I would also suggest, when introducing CTS to the public, the Hospital Authority should include genetic predisposition as one of the important risk factors of CTS, Dr Gao said.

About the Research Team

In collaboration with multiple institutions, the research was led by Dr Gao Bo, Assistant Professor of the School of Biomedical Sciences, HKUMed. Dr Li Chun-yu, China-Japan Union Hospital of Jilin University, Mainland China and Dr Wang Ni, Research Associate, School of Biomedical Sciences, HKUMed are co-first authors. Key international collaborators include Professor Yang Ying-zi, Harvard University, U.S.; Professor Cui Shu-sen, China-Japan Union Hospital of Jilin University, Mainland China and Dr Alejandro Schaffer, National Institutes of Health, U.S.. Other HKU scientists contributing to the research include Professor Danny Chan, S Y and H Y Cheng Professorship in Stem Cell Biology and Regenerative Medicine, Interim Director of School of Biomedical Sciences, HKUMed and Assistant Dean (Research postgraduate studies), HKUMed; Dr Wang Jin, Post-doctoral Fellow, School of Biomedical Sciences, HKUMed; Dr Wang Cheng, former Post-doctoral Fellow, School of Biomedical Sciences, HKUMed; and Ms Vanessa Choi Nga-ting, Technician, School of Biomedical Sciences, HKUMed.

The work was supported in part by Health and Medical Research Fund (Project #05160946) in Hong Kong.

The rest is here:
HKUMed reveals pathogenic gene of carpal tunnel syndrome providing new directions for prevention and treatment - Mirage News

Cancer Biological Theraphy Market Size, Share Global Opportunities, Trends, Regional Overview, Global Growth, Leading Company Analysis, And Key…

By Gene Therapy Clinics

Global Cancer Biological Theraphy Market Report Focuses on the key Cancer Biological Theraphy Market manufacturers, to study the sales, value, market share and development plans in the future. It is Define, describe and forecast the Cancer Biological Theraphy Market by type, application, and region to Study the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. Know significant trends and factors driving or inhibiting the Cancer Biological Theraphy Market growth opportunities in the market for stakeholders by identifying the high growth segments. Strategically it examines each submarket with respect to individual growth trend and their contribution to the Cancer Biological Theraphy Market

Get a sample copy of the report at https://www.marketreportsworld.com/enquiry/request-sample/11430918

The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2020 to 2020.

Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. There are various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as; cancer targeted therapies. The global cancer biological therapy market is expected to reach USD 82,276.8 million by 2023 at a CAGR of 4.7% during the forecasted period. The global cancer biological therapy market is segmented on the basis of phases, types, end users and regions. On the basis of phases, the market is segmented into phase I, phase II and phase III. In stage I & II the real impact of these therapies is seen and giving a success rate of 35% in Phase 1 and 20% in Phase II. The success rate of phase I is 35%.On the basis on types, the global cancer biological therapy market is segmented into monoclonal antibodies, cancer growth blockers, interferons, interleukins, gene therapy, targeted drug delivery, colony stimulating factor, cancer vaccines and others. Monoclonal antibodies accounted for the largest market share of the global cancer biological therapy market. Colony stimulating factor is the fastest growing market at a CAGR of 5.2% during the forecasted period.On the basis on end users, hospitals & clinics dominates the global cancer biological therapy market. Registering USD 26,790.6 million in 2016 and expected to reach at USD 38,471.9 million by 2023 at the rate of 4.4 % from 2016-2023. On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific and the Middle East & Africa. North America has the dominating market for cancer biological therapy. The cancer biological therapy market for North America is estimated at USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%.

Here is List of Top Cancer Biological Theraphy Market Key-Manufactures:

Global Cancer Biological Theraphy market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Cancer Biological Theraphy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Enquire before purchasing this report https://www.marketreportsworld.com/enquiry/pre-order-enquiry/11430918

The overviews, SWOT analysis and strategies of each vendor in the Cancer Biological Theraphy market provide understanding about the market forces and how those can be exploited to create future opportunities. Major points like Competitive Situation and Trends, Concentration Rate Mergers & Acquisitions, Expansion which are vital information to grow/establish a business is also provided.

Key Factors Involved in the Report:

Cancer Biological Theraphy Market Forecast by regions, type and application, with sales and revenue, from 2020 to 2020.

Cancer Biological Theraphy Market Share, distributors, major suppliers, changing price patterns and the supply chain of raw materials is highlighted in the report.

Cancer Biological Theraphy Market Size (sales, revenue) forecast by regions and countries from 2020 to 2020 of Cancer Biological Theraphy industry.

The global Cancer Biological Theraphy market Growth is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2020. In 2020, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Cancer Biological Theraphy Market Trend for Development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Cancer Biological Theraphy Market Report also mentions market share accrued by each product in the Cancer Biological Theraphy market, along with the production growth.

The study objectives of this report are:

Target Audience

Production Analysis: SWOT analysis of major key players of Cancer Biological Theraphy industry based on a Strengths, Weaknesses, companys internal & external environments, Opportunities and Threats. It also includes Production, Revenue, and average product price and market shares of key players. Those data are further drilled down with Manufacturing Base Distribution, Production Area and Product Type.

Regional analysis

Geographically, the global Cancer Biological Theraphy market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Key Features of Cancer Biological Theraphy Market Research Report:

Purchase this report (Price 4450 USD for a single-user license) https://www.marketreportsworld.com/purchase/11430918

Total Chapters in Cancer Biological Theraphy Market Report are:

Chapter 1 Overview of Cancer Biological Theraphy Market

Chapter 2 Global Market Status and Forecast by Regions

Chapter 3 Global Market Status and Forecast by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

Chapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry

Chapter 10 Market Driving Factor Analysis of Low End Servers

Chapter 11 Cancer Biological Theraphy Market Competition Status by Major Manufacturers

Chapter 12 Cancer Biological Theraphy Major Manufacturers Introduction and Market Data

Chapter 13 Upstream and Downstream Market Analysis of Cancer Biological Theraphy Market

Chapter 14 Cost and Gross Margin Analysis of Cancer Biological Theraphy Market

Browse complete table of contents at https://www.marketreportsworld.com/TOC/11430918

About Us:

Market Reports Worldis the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

CONTACT US

Name: Ajay More

Email: [emailprotected]

Phone: US +1 424 253 0807 /UK +44 203 239 8187

Other Reports Here:

Hybrid Power Solutions Market 2020 Global Industry Trends, Size, Segments, Competitors Strategy, Regional Analysis, Review, Key Players Profile, Statistics and Growth to 2026 Analysis

Oilfield Thickener Products Market Growth by Region, Application, Top Companies, Driver, Trends & Forecasts to 2024

Sludge Dewatering Equipments Market Size, Top Countries Data ,Share 2020: Emerging Technologies, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2026

Aerosol Paints Market Size 2020 Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2024

Diagnostic Equipment Market Size 2020Global Industry Analysis, Trends, Market Demand, Growth, Opportunities and Forecast 2025

VoIP Market Share, Size Global Industry Demand, Future Growth, Regional Trend, Leading Players Updates, Current and Future Plans by Forecast to 2026

Read the rest here:
Cancer Biological Theraphy Market Size, Share Global Opportunities, Trends, Regional Overview, Global Growth, Leading Company Analysis, And Key...

Global Ventilators Market Projections & Future Opportunities Recorded for the Period until 2027|ResMed., Medtronic, BD, Getinge AB., Drgerwerk AG…

By Gene Therapy Clinics

Ventilators marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 1662.48 million by 2027 growing at a CAGR of 7.60% in the above-mentioned forecast period. Increasing demand for homecare therapeutic devices and rising cases of pulmonary disorders are the factor which will affect the ventilators market in the forecast period of 2020 to 2027.

This persuasive ventilator market report endows with an exhaustive survey of key players in the market which is based on a range of objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization. This market report is an accurate study of the healthcare industry which gives estimations about new triumphs that will be made in the ventilator market in 2020-2027. The ventilator market document has been prepared to bring about comprehensive analysis of the market structure along with forecast of the different segments and sub-segments of the market.

Download Sample PDF Copy of Reporthttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-ventilators-market&kb

The major players covered in the ventilators market report areKoninklijke Philips N.V., ResMed., Medtronic, BD, Getinge AB., Drgerwerk AG & Co. KGaA,, Smiths Group, Hamilton Medical., GENERAL ELECTRIC COMPANY, Fisher & Paykel Healthcare Limited., Air Liquide., Asahi Kasei Corporation., Skanray Technologies Pvt. Ltd, WEINMANN Emergency Medical Technology GmbH + Co. KG, SCHILLER, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Airon Corporation, ZOLL Medical Corporation., among other domestic and global players. Market Share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Market Trends

On the basis of product type, the global ventilator market is segmented into intensive care ventilators, portable ventilators and neonatal ventilators. Intensive care ventilators are further sub-segmented into high-end ICU ventilators, basic ICU ventilators and mid-end ICU ventilators. In 2018, Intensive care ventilators segment is growing at the highest CAGR and expected to reach USD in the forecast period of 2018 to 2025.

On the basis of modality, the global ventilator market is segmented into non-invasive ventilation and invasive ventilation. Non-invasive ventilation is sub-segmented into volume-cycled ventilators, pressure-cycled ventilators, continuous positive airway pressure ventilators, bi-level positive airway pressure ventilators, flow-cycled ventilators and time-cycled ventilators. In 2018, Invasive ventilation segment is growing at a specific CAGR. However non-invasive ventilation segment is growing at the highest CAGR in the forecast period of 2018 to 2025.

To know more about the study @https://www.databridgemarketresearch.com/reports/global-ventilators-market

OPPORTUNITIES

Demand for Cost-saving Technologies

Mechanical ventilation is an integral and expensive part of the intensive care unit (ICU). Optimal application of mechanical ventilation could save costs and improve outcomes of patients. In the low economic countries such as India, shortages of ventilation can results into poor treatment of the patients. Increasing number of the patients with the chronic diseases associated with the respiratory issues demands more ventilation system; hence the demand of the low cost ventilators can enhance the ventilator market in coming year

To register for digital conference click here @https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy

Segmentation: Global Ventilators Market

Ventilators market is segmented of the basis of mobility, interface, mode, end- users, and product type. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on mobility,

the ventilators market is segmented into intensive care ventilators and portable/transportable ventilators. Intensive care ventilators market is segmented into high-end ICU ventilators, mid-end ICU ventilators and basic ICU ventilators.

On the basis of interface,

the ventilator market is segmented into invasive ventilation and non- invasive ventilation.

Ventilators market on the basis of mode

is also segmented into combined- mode, volume mode ventilation, pressure- mode ventilation and other.

The end user segment of the ventilators market is segmented into hospitals & clinics, home care, ambulatory care centers and emergency medical services.

On the basis of product type,

the ventilators market is divided into Intensive care, portable and neonatal.

The ventilators market is also segmented on the basis of type. The type is segmented into adult, paediatrics and neonatal.

Inquire Regarding This Report @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-ventilators-market&kb

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:[emailprotected]

Read more:
Global Ventilators Market Projections & Future Opportunities Recorded for the Period until 2027|ResMed., Medtronic, BD, Getinge AB., Drgerwerk AG...

Ligament Repair Procedures Market 2020 Global Industry Analysis By Size, Growth Rate, Share and Trends With Forecast To 2027 – Owned

By Gene Therapy Clinics

Latest study released by Data Bridge Market Research on Global Ligament Repair Procedures Market Size, Share, Growth, Industry Research with more than 220 market data tables and figures spread through Pages are easy to understand TOC in Global Ligament Repair Procedures Market research, so you can get a variety of ways to maximize your profits. Ligament Repair Procedures business research report has market data and information which can answer several marketing problems in different functional areas of marketing such as consumer behaviour, product, sales, distribution channel, pricing, ad and physical distribution. The report provides data on patterns and improvements, and target business sectors and materials, limits and advancements. This report comprises a chapter on the global Ligament Repair Procedures market and all its associated companies with their profiles, which gives valuable data pertaining to their outlook in terms of finances, product portfolios, investment plans, and marketing and business strategies. Ligament Repair Procedures Market predicted until 2027.

Global Cruciate Ligament Repair Procedures Market is expected to rise to an estimated value of USD 17.42 billion by 2026, registering a healthy CAGR in the forecast period of 2019-2026.

Get FREE Sample Report + To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cruciate-ligament-repair-procedures-market

(Note-Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology) Competitive Analysis:

The key players are highly focusing innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies. Company profile section of players such as Xiros, Medical Devices Business Services, Stryker, Corin, Smith+Nephew, Mathys Ltd Bettlach, GROUP FH ORTHO communication, Artelon, Zimmer Biomet, Colfax, CONMED, Bauerfeind, ?ssur Corporate, Ottobock, United Orthopedic Corp, Exactech, Wright Medical Group N.V., Breg, MicroPort Scientific, Fuse Medical among others.

Highlights of the Report

The report offers a 360-degree overview of the Cruciate Ligament Repair Procedures Market, primarily emphasizing on growth drivers, restraints, market trends, size, share, growth, challenges, new recent developments and opportunities of the market.

It provides elaborative information about the competitive landscape of the market, names of market vendors, market segmentation on the basis of application, type, and others, and current logging-while-drilling market trends and industry developments.

The report also throws light on strategies such as company collaborations, mergers and acquisitions, production analysis, application niches and dominance, product approvals, product launches, geographical expansions, technological innovations and up-gradation of the older versions, investments in research and development, and other strategies adopted by the market players.

Browse Full Report with Details TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-cruciate-ligament-repair-procedures-market Market Drivers o Increasing incidence of accidents, sports injures may lead to the growth of the market o Advancement in the technique of surgery will drive the market growth o Increase in geriatric population with rising level of obesity and number of diseases will also augment the growth of this market in the forecast period o Increase research and development activities coupled with innovative therapies acts as a market driver Market Restraints o High cost associated with knee related surgery hampers the market growth o Dearth of skilled and trained physicians will impede the growth of the market o Poor quality of healthcare system in developing countries will also restrict the market growth

Global Cruciate Ligament Repair Procedures Market Detailed Segmentation:

By Type (PCL, ACL), Injury Type (Grade I, Grade II, Grade III), Product (Cemented Implants, Cement-Less Implants, Partial Implants, Revision Implants), Indication (Osteoarthritis, Rheumatoid Arthritis, Trauma, Others), Diagnosis (Imaging, Others) Treatment (Surgery, Therapies, Devices, Others)

By End-User (Hospitals, Orthopedic Clinics, ASC, Others)

By Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa)

List of the Leading Companies that are operating in the global Cruciate Ligament Repair Procedures Market are: Xiros, Medical Devices Business Services, Inc., Stryker, Corin, Smith+Nephew, Mathys Ltd Bettlach, GROUP FH ORTHO communication, Artelon, Zimmer Biomet, Colfax Corporation, CONMED Corporation, Bauerfeind, ?ssur Corporate, Ottobock, United Orthopedic Corp, Exactech, Inc., Wright Medical Group N.V., Breg, Inc., MicroPort Scientific Corporation, Fuse Medical among others.

For More Information or Query or Customization Before Buying, Visit @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cruciate-ligament-repair-procedures-market

The Cruciate Ligament Repair Procedures Market report highlights the key players and the latest strategies including company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, new product launches, partnerships, joint ventures, product width and breadth, application dominance, technology lifeline curve, segmentation in terms of region and industry competition, profit and loss ratio, and investment ideas.

The Cruciate Ligament Repair Procedures report has been produced with the systematic gathering and analysis of information about individuals or organizations conducted through social and opinion research. With the studies, insights and analysis mentioned in the report, you get comprehensible idea about the marketplace with which you can take business decisions quickly and easily.

The worldwide Cruciate Ligament Repair Procedures advertise report comprises of all the organization profiles of the key players and brands. Market definition covered in this Cruciate Ligament Repair Procedures report studies the market drivers and market restraints with which businesses can get idea of whether to increase or decrease the production of a particular product.

Global Cruciate Ligament Repair Procedures Market Report includes Major Detailed Table of Content Points: Table of Content

1Introduction 2Market Segmentation 3 Market Overview 4 Executive Summaries 5 Premium Insights 6 Regulatory Procedure 7 Global Cruciate Ligament Repair Procedures Market, By Type 8 Global Cruciate Ligament Repair Procedures Market, by Product type 9 Global Cruciate Ligament Repair Procedures Market, By Deployment 10 Global Cruciate Ligament Repair Procedures Market, By End User 11 Global Cruciate Ligament Repair Procedures Market, By Distribution Channel 12 Global Cruciate Ligament Repair Procedures Market, By Geography 13 Global Cruciate Ligament Repair Procedures Market, Company Landscape 14 Company Profile Continued!!!

Contact Us:

Data Bridge Market Research US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475 Email:[emailprotected]

Our Upcoming Event: CELL AND GENE THERAPY|Digital Conference

Cell and Gene therapy (CGT) is considered as one of the most progressive advancements in this new ecosystem with extensive evaluations of multiple diseases and upcoming technologies. With the ongoing enhancements in CGT the potential to transform medicine increases which has brought a significant change for the treatment and potential cure of many intractable illnesses.In recent years, these therapies have proved clinically to be life-saving and also promise to offer personalization treatment for several diseases such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS.

REGISTER NOW FOR FREE Gene Therapy[emailprotected]https://www.databridgemarketresearch.com/digital-conference/cell-and-gene-therapy?ab

Cell and Gene therapy continues to be a prominent and active area of research in genomics and cell biology which have permitted exciting progress in the development of novel and effective treatments for various diseases. With cell and gene therapies finally becoming a reality with ongoing hundreds of clinical trials and some of the major therapeutics breakthroughs already reaching the market, it is expected soon their will large number of approvals and launches in the market. So lets come together to discuss the future of cell and gene therapy along with their applications, challenges and regulatory scenario.

In the pioneer edition ofDBMR Cell and Gene Therapy Conferencecome join us in this enriching knowledge fest where experts will speak on new technologies and market dynamics perceptions. Together lets move ahead in the future of medical science and technology.

Read more here:
Ligament Repair Procedures Market 2020 Global Industry Analysis By Size, Growth Rate, Share and Trends With Forecast To 2027 - Owned

Fair Haven Foundation provides a refuge in the storm – WRTV Indianapolis

By Stem Cell Doctors

INDIANAPOLIS Living through a global pandemic with shutdowns, job losses, and health scares can be difficult for anyone. But for those who are battling a serious health threat, it can be even more of a challenge.

Thousands of people come to Indianapolis each year to receive life-saving transplants and chemotherapy from doctors here in downtown.

"If you are in the middle of a health crisis like they are, it's been even tougher, and thankfully Indianapolis hospitals haven't been overwhelmed by Covid patients so they've been able to continue to care for the most critically ill," says Amanda Milner who founded Fair Haven Foundation.

Fair Haven is just what the name references, a refuge in the storm. The organization provides housing, free of charge, to patients and their families at Indianapolis hospitals while they undergo treatment away from home.

Each year, Fair Haven can provide shelter and basic household necessities to around 100 families who stay, on average, four weeks in their apartments.

Milner knows firsthand there is a need after working for a cancer agency and then being diagnosed herself.

At the age of 3, Milner was a single mother to two kids and was diagnosed with cancer. She was unable to work and lost her home, but not her faith, as she relied on the support of her family, friends, and God to get her through the tough times.

"Through it, I had so much to be grateful for, and so I started Fair Haven as a way to share the love from my family and friends and my Heavenly Father and give that to people who are in that same battle," says Milner.

The apartments are fully furnished, with two bedrooms, two bathrooms. They include a full kitchen and living room and are located close to the medical facilities here in Indianapolis.

Patients like Derek Brown are thankful this service exists as he found himself in an unthinkable spot.

Brown is a Gary native and a Purdue grad, who has worked all over the United States, but his family roots brought him back to the Hoosier state. He was just about to sign papers to start a new career when something felt off.

"Something isn't right. My head was still hurting a lot, mouth sores were still there, so we go to the emergency room," says Brown. "They run all these batteries of tests, Cat scans, CT scans, etc. They keep me overnight, and then I wake up the next morning, and they tell me, oh ya, you have leukemia."

He considered getting a second opinion, but time wasn't on his side. Doctors needed to start an aggressive treatment right away.

"So they put me in the back of an ambulance and 2 hours and 50-minute drive down here, and I got here February 20th and met with the team of doctors," says Brown. "They pretty much confirmed that I had Acute Myeloid Leukemia with a mutation, unfortunately."

Treatment in Indianapolis started right away.

"So we put everything in the hands of the Lord and got started," says Brown. "So it was aggressive, that first week."

To brighten his spirits during treatments, his parents and family would visit as well as friends. Then March came, and COVID-19 came to Indianapolis.

"That was big. It was huge. It was good for my psyche and just overall just seeing people seeing friends and faces, which was good, but then all of a sudden, they were like sorry we are going to have to cut that out."

Brown knew he needed a stem cell transplant, and he has an older brother. He and his family were thankful when they found out his brother was a perfect match. The procedure was a success, but he still needed to spend a lot of time recovering in Indianapolis and going to follow up appointments and be near his doctors.

He applied for an apartment with Fair Haven, which always has a waiting list, and thankfully an apartment opened up just in time.

"I don't even know where to begin," says Brown. "Fair Haven, it's been, its been great ... Words can't even put into play how much they've been there, ya know, from day one helping me out."

Milner and others from Fair Haven helped Brown and his family move into the apartment. Brown, who went vegan and lost a lot of weight before his diagnosis, could cook healthy food in his kitchen so he could stay on top of his health. His parents had their own room to rest while he was getting treatments.

"And just my parents as well, too. Having a place for them to be comfortable, it's been great. Having a place for them to rest and be at ease as well, too, when I'm at the hospital, be it transfusions or follow-ups, so its been huge. It checks all the marks."

Brown and his parents have already discussed supporting Fair Haven in any way they can going forward, to give back to a place that means so much.

"I'm very fortunate that I was able to get blessed and get this, and then hopefully, I can continue to help out and be a part of it moving on," says Brown. "Kind of like being a home away from home."

Due to COVID-19, Fair Haven had to postpone their biggest fundraiser of the year from Spring to summer, and with the rise in cases, it has now moved to a virtual platform.

You can watch their "Stories of Hope" on their Facebook page.

And find out how you can donate at FairHavenFoundation.org.

Right now, they own a building debt-free, and once renovations are complete, they will be able to serve 600 families a year, on average. Right now, Fair Haven needs support to renovate the space and prepare it for these patients.

The goal is to open this new facility by the spring of 2021.

Read the original here:
Fair Haven Foundation provides a refuge in the storm - WRTV Indianapolis

Canine Stem Cell Therapy Market Segment Analysis by Leading Players, Drivers, Regional, Competitive Landscape & Forecast To 2019 2029 – Owned

By Stem Cell Treatment

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare Current expenditure on health, % of gross domestic product Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs) Annual growth rate of current expenditure on health, per capita, in real terms Out-of-pocket expenditure, % of current expenditure on health Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs) Physicians, Density per 1000 population (head counts) Nurses, Density per 1000 population (head counts) Total hospital beds, per 1000 population Curative (acute) care beds, per 1000 population Medical technology, Magnetic Resonance Imaging units, total, per million population Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

This Press Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.xploremr.com/connectus/sample/2360

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Request Report Methodology at https://www.xploremr.com/connectus/request-methodology/2360

Standard Report Structure Executive Summary Market Definition Macro-economic analysis Parent Market Analysis Market Overview Forecast Factors Segmental Analysis and Forecast Regional Analysis Competition Analysis

Target Audience Production Companies Suppliers Channel Partners Marketing Authorities Subject Matter Experts Research Institutions Financial Institutions Market Consultants Government Authorities

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type: Allogeneic Stem Cells Autologous Stem cells

Application: Arthritis Dysplasia Tendonitis Lameness Others

End User: Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

Region: North America Latin America Europe Asia Pacific Japan Middle East & Africa

Buy Full Report at https://www.xploremr.com/cart/2360/SL

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis.

Contact us: XploreMR 111 North Market Street, Suite 300, San Jose, CA 95113, United States Ph.No: +16692840108 E-mail id- [emailprotected] Web- https://www.xploremr.com

See the original post:
Canine Stem Cell Therapy Market Segment Analysis by Leading Players, Drivers, Regional, Competitive Landscape & Forecast To 2019 2029 - Owned

Researchers Discover a New Side of Cancer that May Explain Its Resistance to Treatment – Genetic Engineering & Biotechnology News

By Embryonic Stem Cells

Cancers ability to resist chemotherapy has been a roadblock to achieving lasting remissions or cures. Scientists have believed that unique genetic mutations in tumors may be to blame for drug resistance. However, they are starting to look at nongenetic changes in cancer cells to explain their adaptability. An example of this is cancers ability to change its identity. A prostate cancer cell that is sensitive to hormone-blocking therapy might change into a cell type that does not require the hormone for its growth. This heterogeneity creates obstacles for treatment, since a single drug is unlikely to work against so many different cell types.

Now, a team of researchers at the Sloan Kettering Institute (SKI), the Koch Institute for Integrative Cancer Research at MIT, and the Klarman Cell Observatory at the Broad Institute have discovered that this tumor heterogeneity can be traced back to a common source: a particularly flexible cell state that is characteristic of a subset of cells in a tumor and can generate many other diverse cell types.

Their study, Emergence of a High-Plasticity Cell State during Lung Cancer Evolution, is published in Cancer Cell and led by Tuomas Tammela, MD, PhD, an assistant member in the cancer biology and genetics program at SKI.

The high-plasticity cell state is the starting point for much of the heterogeneity we see in tumors, stated Tammela. Its kind of like a busy intersection of many roads: Wherever a cell wants to end up identity-wise, it has to go through this cell state.

Tumor evolution from a single cell into a malignant, heterogeneous tissue remains poorly understood. Here, we profile single-cell transcriptomes of genetically engineered mouse lung tumors at seven stages, from pre-neoplastic hyperplasia to adenocarcinoma, the researchers wrote.

This highly plastic cell state is something completely new, stated Jason Chan, MD, PhD, a physician-scientist doing a fellowship in the Tammela lab and one of the papers lead authors. When we saw it, we didnt know what it was because it was so different. It didnt look like normal lung cells where the cancer came from, and it didnt really look like lung cancer either. It had features of embryonic germ layer stem cells, cartilage stem cells, and even kidney cells, all mixed together.

The researchers observed these cells in every tumor they examined and identified these highly plastic cells by single cell RNA sequencing (scRNA-Seq). By performing scRNA-Seq on tumors as they grew over time, the researchers were able to observe when and how different cell types emerged over the course of a tumors evolution. From these data, the researchers were able to create a kind of map of which cells came from which other cells.

The map contains major highways and little dirt roads, Tammela explained. The high-plasticity cell state that we identified sits right in the middle of the map. It has a lot of paths coming in, and it has even more paths coming out.

This high-plasticity cell state emerged consistently in a tumors evolution and persisted throughout its growth.

Stem cells play important roles in embryonic development and in tissue repair. Many scientists think that cancers arise from specific cancer stem cells. But Tammela and colleagues do not think these high-plasticity cells are stem cells. Unlike stem cells, the cells are not present at the very beginning of a tumors growth, and emerge later.

When we compare the gene expression signature of these highly plastic cells to normal stem cells or known cancer stem cells, the signatures dont match at all. They look completely different, he said.

Cancer cells progressively adopt alternate lineage identities, computationally predicted to be mediated through a common transitional, high-plasticity cell state (HPCS). Accordingly, HPCS cells prospectively isolated from mouse tumors and human patient-derived xenografts display high capacity for differentiation and proliferation. The HPCS program is associated with poor survival across human cancers and demonstrates chemoresistance in mice. Our study reveals a central principle underpinning intra-tumoral heterogeneity and motivates therapeutic targeting of the HPCS, noted the researchers.

Our model could explain why certain cancer cells are resistant to therapy and dont have a genetic basis for that resistance that we can identify, Chan stated.

Chan also explained it is not all the cells in the tumor that are adapting, but a subset of the cancer cells that are just more malleable.

The researchers believe it may be possible to avert the emergence of resistance and provide lasting remission by combining chemotherapy drugs with new medications that target these highly plastic cells.

Originally posted here:
Researchers Discover a New Side of Cancer that May Explain Its Resistance to Treatment - Genetic Engineering & Biotechnology News

First-ever bone marrow transplant successfully conducted in UAE – WAM EN

By Stem Cell Treatment

ABU DHABI, 27th July, 2020 (WAM) -- In a landmark announcement of the first-ever bone marrow transplant successfully conducted in the UAE, Abu Dhabi Stem Cells Centre, ADSCC, today inaugurated the Abu Dhabi Bone Marrow Transplant programme, AD-BMT.

Typically used to treat patients with hematological and oncological illnesses, the bone marrow transplant was performed on a patient with multiple myeloma, a form of blood cancer. Though cancer is the third-highest cause of death in the UAE, Emirati citizens and residents have often sought treatment abroad for cell therapy and regenerative medicine.

The successful transplant, which was the result of collaboration between ADSCC and Sheikh Khalifa Medical City, represents a groundbreaking advancement for cancer patients living in the UAE who can now seek treatment closer to home to remain with family.

Bone marrow transplants, or hematopoietic stem cell transplantation, are one of the most established stem cell-based therapies in the treatment of cancer, particularly blood cancers. The unique treatment procedure developed by ADSCC, involved harvesting peripheral blood stem cells from the patient, who then underwent high-dose chemotherapy to eradicate all cancerous cells and most of the bone marrow. The harvested stem cells were then infused back into the bloodstream, where they restore the destroyed cells and over the course of two weeks restart the production of healthy non-malignant blood cells.

"The patient is basically without an immune system while waiting for the transfused cells to take effect and must remain in isolation under the strictest infection control guidelines," said Dr. Yendry Ventura, General Manager of ADSCC and BMT Programme Director. "Since we are still in the midst of a global pandemic, we took additional precautions to ensure the best outcome possible for all involved."

Earlier last month, ADSCC announced the results of the trial of its breakthrough treatment for COVID-19 patients, branded UAECell19, demonstrating its remarkable safety and efficacy. UAECell19 went on to secure three levels of intellectual property protection in recognition of its originality and novel medical application. Moreover, todays announcement of the Abu Dhabi Bone Marrow Transplant programme demonstrates ADSCCs continued commitment to delivering state-of-the-art and evidence-based services to the UAE market, including an array of stem cell therapies. It aims to make the BMT treatment available to all patients in the UAE who require it.

"It fills us with great pride to be part of a first for the country and to make such a life-saving treatment available and accessible to those who need it here," said Dr. Fatima Alkaabi, BMT Executive Director. "We are very grateful for the support and collaboration of SKMC in making this opportunity possible."

ADSCC was founded with the primary objective of meeting growing domestic and regional demand for advanced medical services and most innovative treatments in the UAE. ADSCC is committed to ensuring the Abu Dhabi Bone Marrow Transplant programme meets the highest standards of quality and patient satisfaction at all steps of the process, including treatment, aftercare, and follow-up between clinical BMT personnel, patients, and their families.

More here:
First-ever bone marrow transplant successfully conducted in UAE - WAM EN

→←